Jardiance Met is used to treat the following -
Main Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
Based on research, the following side effects have been observed when Jardiance Met is used -
Severe
Moderate
Mild
Common
Is the use of Jardiance Met safe for pregnant women?
Jardiance Met should not be taken during pregnancy, or should only be taken on the advice of a doctor as it may have severe side effects.
Is the use of Jardiance Met safe during breastfeeding?
Women who are breastfeeding can experience some moderate side effects of Jardiance Met. Immediately discontinue Jardiance Met if you observe any side effects. Contact your doctor, and restart using it only if your doctor considers it safe for you.
What is the effect of Jardiance Met on the Kidneys?
Jardiance Met has very mild side effects on the kidneys.
What is the effect of Jardiance Met on the Liver?
Using Jardiance Met does not have any harmful effects on the liver.
What is the effect of Jardiance Met on the Heart?
Jardiance Met is rarely harmful for the heart.
Jardiance Met should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Jardiance Met unless your doctor advises you to do so -
Is this Jardiance Met habit forming or addictive?
Jardiance Met does not cause addiction.
Interaction between Food and Jardiance Met
You can take Jardiance Met with food.
Interaction between Alcohol and Jardiance Met
Taking Jardiance Met with alcohol can have severely harmful effects on your health.
Jardiance Met is used with a proper diet and exercise program, to treat diabetes. It is also used with other medication to reduce the high blood sugar. It is used in a patient with type2 diabetes. It is also used in the treatment of polycystic ovarian syndrome (PCOS) and cancer.
Jardiance Met is not a known cause of alopecia (hair loss). However, the conditions treated by Jardiance Met type 2 diabetes and PCOS, often list hair loss as a possible symptom.
Jardiance Met contain metformin, is an oral antidiabetic drug which belongs to the class of biguanide. It is the first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight. It is also used in the treatment of polycystic ovary syndrome. Moreover, it also reduces the risk of cardiovascular complications of diabetes.
Yes, Jardiance Met can be taken with the statin. There is no serious or harmful interaction have been observed between them. Some studies say that it's possible your blood sugar (blood glucose) level may increase when you take a statin, which may lead to developing type 2 diabetes. The risk is small but important enough that the Food and Drug Administration (FDA) has issued a warning on statin labels regarding blood glucose levels and diabetes.
Yes, Jardiance Met is safe to use, many people have side effects at first, they usually diminish and then go away completely in a few weeks. A few people find they cannot tolerate metformin, there are other drugs but metformin is usually the first choice. It is very safe
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Glucophage® (metformin hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 275-276
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 825-826
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Jardiance® (empagliflozin)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 491-493